SG11201804890TA - Bipyrazolyl derivatives useful for the treatment of autoimmune diseases - Google Patents

Bipyrazolyl derivatives useful for the treatment of autoimmune diseases

Info

Publication number
SG11201804890TA
SG11201804890TA SG11201804890TA SG11201804890TA SG11201804890TA SG 11201804890T A SG11201804890T A SG 11201804890TA SG 11201804890T A SG11201804890T A SG 11201804890TA SG 11201804890T A SG11201804890T A SG 11201804890TA SG 11201804890T A SG11201804890T A SG 11201804890TA
Authority
SG
Singapore
Prior art keywords
ridgefield
box
legal
ridgebury
boehringer ingelheim
Prior art date
Application number
SG11201804890TA
Inventor
Todd Bosanac
Joerg Bentzien
Michael Jason Burke
Ryan Michael Fryer
Eric Thomas Larson
Matt Aaron Tschantz
Bryan Patrick Mckibben
Wang Mao
Yue Shen
Fariba Soleymanzadeh
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of SG11201804890TA publication Critical patent/SG11201804890TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization M1111101110101011111 HO 1111101110101101100111 01111101111111011 11 International Bureau .. .... ..Yejd (10) International Publication Number (43) International Publication Date ..... .....!;,' WO 2017/106429 A2 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: Not classified Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut 06877-0368 (21) International Application Number: (US). FRYER, Ryan Michael [US/US]; c/o VP, IP Legal, PCT/US2016/066799 Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., (22) International Filing Date: P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). 15 December 2016 (15.12.2016) LARSON, Eric Thomas [US/US]; c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 Ridgebury Rd., (25) Filing Language: English P.O. Box 368, Ridgefield, Connecticut 06877-0368 (US). (26) Publication Language: English MAO, Wang [CN/US]; c/o VP, IP Legal, Boehringer In- gelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, (30) Priority Data: Ridgefield, Connecticut 06877-0368 (US). MCKIBBEN, 62/268,278 16 December 2015 (16.12.2015) US Bryan Patrick [US/US]; c/o VP, IP Legal, Boehringer In- 62/431,008 7 December 2016 (07.12.2016) US gelheim USA Corp., 900 Ridgebury Rd., P.O. Box 368, (71) Applicant: BOEHRINGER INGELHEIM INTERNA- Ridgefield, Connecticut 06877-0368 (US). SHEN, Yue TIONAL GMBH [DE/DE]; Boehringer Ingelheim GmbH, [CN/US]; c/o VP, IP Legal, Boehringer Ingelheim USA Corporate Patents, Binger Strasse 173, 55216 Ingelheim Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Con- am Rhein (DE). necticut 06877-0368 (US). SOLEYMANZADEH, Fariba [CA/US]; c/o VP, IP Legal, Boehringer Ingelheim USA (72) Inventors; and Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Con- (71) Applicants (for US only): BOSANAC, Todd [US/US]; necticut 06877-0368 (US). TSCHANTZ, Matt Aaron c/o VP, IP Legal, Boehringer Ingelheim USA Corp., 900 [US/US]; c/o VP, IP Legal, Boehringer Ingelheim USA Ridgebury Rd., P.O. Box 368, Ridgefield, Connecticut Corp., 900 Ridgebury Rd., P.O. Box 368, Ridgefield, Con- = 06877-0368 (US). BENTZIEN, Joerg [DE/US]; c/o VP, necticut 06877-0368 (US). = IP Legal, Boehringer Ingelheim USA Corp., 900 Ridge- — bury Rd., P.O. Box 368, Ridgefield, Connecticut 06877- _ 0368 (US). BURKE, Michael Jason [US/US]; c/o VP, IP = [Continued on next page] (54) Title: = 10 = > ›-. . _ ,0 CO 0 10 0 > 8 - co = I .E - g z 6 g = a E 4 HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS p 0.06 erg. Control , (57) : The present invention encompasses com- pounds of the formula (I) wherein the groups R I , Cy and Y are defined herein, which are suitable for the treatment of dis - eases related to BTK, and processes for making these com- pounds, pharmaceutical preparations containing these com- * pounds, and their methods of use. 2 2 — - .,- - 0.) 2 c\".1 = C6 — = = 0 0 = Example Cmpd. B Cmpd. A Cmpd. C Ex. 12 Ex. 22 Doee 10 30 10 30 10 30 10 30 10 30 = FIG. 1 ei H 2 N Cy 01 ei \ 71- HN , N N / 0 Ri Y 1-1 (1) IN 1-1 0 ei O WO 2017/106429 A2111110H3101010ig11013010111001111 1111EE1101 IIE (74) (81) Agents: MORRIS, Michael P. et al.; Boehringer Ingel- heim Pharmaceuticals, Inc., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). Designated States (unless otherwise indicated, for every GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, Declarations under Rule 4.17: GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, — as to applicant's entitlement to apply for and be granted KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, a patent (Rule 4.17(0) NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, Published: (84) QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, without international search report and to be republished upon receipt of that report (Rule 48.2(g))
SG11201804890TA 2015-12-16 2016-12-15 Bipyrazolyl derivatives useful for the treatment of autoimmune diseases SG11201804890TA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562268278P 2015-12-16 2015-12-16
US201662431008P 2016-12-07 2016-12-07
PCT/US2016/066799 WO2017106429A2 (en) 2015-12-16 2016-12-15 Heteroaromatic compounds as btk inhibitors

Publications (1)

Publication Number Publication Date
SG11201804890TA true SG11201804890TA (en) 2018-07-30

Family

ID=58737849

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201804890TA SG11201804890TA (en) 2015-12-16 2016-12-15 Bipyrazolyl derivatives useful for the treatment of autoimmune diseases

Country Status (31)

Country Link
US (6) US9975882B2 (en)
EP (1) EP3390390B1 (en)
JP (1) JP6976947B2 (en)
KR (1) KR20180095655A (en)
CN (1) CN108368086B (en)
AU (1) AU2016370743B2 (en)
BR (1) BR112018011969B1 (en)
CA (1) CA3005268A1 (en)
CL (1) CL2018001569A1 (en)
CO (1) CO2018005954A2 (en)
CY (1) CY1124749T1 (en)
DK (1) DK3390390T3 (en)
EA (1) EA034561B1 (en)
ES (1) ES2897910T3 (en)
HK (1) HK1256795A1 (en)
HR (1) HRP20211845T1 (en)
HU (1) HUE056877T2 (en)
IL (1) IL259281B (en)
LT (1) LT3390390T (en)
MX (1) MX2018007333A (en)
MY (1) MY197440A (en)
PE (1) PE20181074A1 (en)
PH (1) PH12018501248A1 (en)
PL (1) PL3390390T3 (en)
PT (1) PT3390390T (en)
RS (1) RS62525B1 (en)
SA (1) SA518391864B1 (en)
SG (1) SG11201804890TA (en)
SI (1) SI3390390T1 (en)
TW (1) TWI726017B (en)
WO (1) WO2017106429A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882741B1 (en) 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
TWI726017B (en) * 2015-12-16 2021-05-01 德商百靈佳殷格翰國際股份有限公司 Heteroaromatic compounds as btk inhibitors
CA3008488C (en) 2015-12-16 2023-10-10 Loxo Oncology, Inc. Compounds useful as kinase inhibitors
US10570118B2 (en) 2016-01-13 2020-02-25 Boehringer Ingelheim International Gmbh Isoquinolones as BTK inhibitors
JP7166331B2 (en) * 2017-08-01 2022-11-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Intermediate compounds and methods
CA3108065A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
MX2021014161A (en) * 2019-05-23 2022-01-04 Novartis Ag Methods of treating sjã–gren's syndrome using a bruton's tyrosine kinase inhibitor.
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
WO2023110970A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Macrocyclic btk inhibitors
WO2023110936A1 (en) 2021-12-14 2023-06-22 Netherlands Translational Research Center Holding B.V Reversible macrocyclic kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9608435D0 (en) 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
WO2001056993A2 (en) * 2000-02-05 2001-08-09 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of erk
WO2003015776A1 (en) 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
AU2002366440A1 (en) 2001-09-27 2003-09-09 Smithkline Beecham Corporation Chemical compounds
FR2881426B1 (en) 2005-02-03 2007-03-30 Aventis Pharma Sa SUBSTITUTED PYROLLES AND IMIDAZOLES, COMPOSITIONS CONTAINING THE SAME, PROCESS FOR FRABRICATION AND USE
ATE534632T1 (en) 2006-04-11 2011-12-15 Vertex Pharma THIAZOLES, IMIDAZOLES AND PYRAZOLES AS PROTEIN KINASE INHIBITORS
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CA3143428A1 (en) 2007-03-28 2008-10-09 Pharmacyclics Llc 8-amino-3-substituted-imidazo[1,5-a]pyrazine and use thereof as inhibitors of bruton's tyrosine kinase
EP2310528B1 (en) 2008-07-29 2013-11-20 Université de Liège A genetic marker test for brachyspina and fertility in cattle
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2750935A1 (en) 2009-01-30 2010-08-12 Millennium Pharmaceuticals, Inc. Heteroaryls and their use as pi3k inhibitors
BR112012014884A2 (en) 2009-12-17 2016-03-22 Merck Patent Gmbh sphingosine kinase inhibitors
LT2578585T (en) 2010-05-31 2016-10-10 Ono Pharmaceutical Co., Ltd. Purinone derivative as btk kinase inhibitor
EP2603216A4 (en) 2010-08-11 2013-12-18 Millennium Pharm Inc Heteroaryls and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CA2863239C (en) * 2012-01-31 2016-09-13 Beta Pharma Canada Inc. Cyclic molecules as bruton's tyrosine kinase inhibitors
EP2882741B1 (en) * 2012-08-10 2018-10-24 Boehringer Ingelheim International GmbH Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
AU2013340345B2 (en) 2012-11-02 2016-10-27 Pfizer Inc. Bruton's tyrosine kinase inhibitors
CN103848810A (en) * 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 Bruton's tyrosine kinases inhibitor
US8895750B2 (en) * 2013-03-14 2014-11-25 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
WO2015116485A1 (en) * 2014-01-29 2015-08-06 Boehringer Ingelheim International Gmbh Pyrazole compounds as btk inhibitors
TWI726017B (en) * 2015-12-16 2021-05-01 德商百靈佳殷格翰國際股份有限公司 Heteroaromatic compounds as btk inhibitors

Also Published As

Publication number Publication date
HUE056877T2 (en) 2022-03-28
CA3005268A1 (en) 2017-06-22
PH12018501248A1 (en) 2019-01-28
EP3390390B1 (en) 2021-09-01
MY197440A (en) 2023-06-19
SA518391864B1 (en) 2021-12-13
AU2016370743B2 (en) 2020-11-26
LT3390390T (en) 2021-11-25
PE20181074A1 (en) 2018-07-04
BR112018011969A2 (en) 2018-12-04
HK1256795A1 (en) 2019-10-04
IL259281A (en) 2018-07-31
DK3390390T3 (en) 2021-12-06
JP6976947B2 (en) 2021-12-08
TWI726017B (en) 2021-05-01
WO2017106429A3 (en) 2017-08-17
CO2018005954A2 (en) 2018-07-10
CN108368086B (en) 2021-01-08
WO2017106429A2 (en) 2017-06-22
US20180030037A1 (en) 2018-02-01
US9975882B2 (en) 2018-05-22
US20170174663A1 (en) 2017-06-22
ES2897910T3 (en) 2022-03-03
CN108368086A (en) 2018-08-03
PL3390390T3 (en) 2022-01-24
RS62525B1 (en) 2021-11-30
IL259281B (en) 2021-04-29
HRP20211845T1 (en) 2022-03-04
BR112018011969B1 (en) 2023-02-23
AU2016370743A1 (en) 2018-05-24
US20180222893A1 (en) 2018-08-09
EA201891399A1 (en) 2019-01-31
TW201731838A (en) 2017-09-16
EP3390390A2 (en) 2018-10-24
PT3390390T (en) 2021-11-18
EA034561B1 (en) 2020-02-20
MX2018007333A (en) 2018-08-24
KR20180095655A (en) 2018-08-27
CY1124749T1 (en) 2022-07-22
JP2019505491A (en) 2019-02-28
CL2018001569A1 (en) 2018-10-05
US20210009567A1 (en) 2021-01-14
US20190092759A1 (en) 2019-03-28
SI3390390T1 (en) 2021-12-31
US20200055843A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
SG11201804890TA (en) Bipyrazolyl derivatives useful for the treatment of autoimmune diseases
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201909344SA (en) Anti-lag3 antibodies
SG11201807539UA (en) Heterocyclic compound
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201809627QA (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201806863WA (en) Tetracyclic pyridone compounds as antivirals
SG11201805888SA (en) Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
SG11201900689RA (en) Compounds and compositions and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201804885TA (en) Monomaleimide-functionalized platinum compounds for cancer therapy
SG11201809162XA (en) 6-aminopyridin-3-yl thiazoles as modulators of ror?t
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201901394XA (en) Neisseria meningitidis vaccine
SG11201811712QA (en) 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
SG11201806622PA (en) Egfl6 specific monoclonal antibodies and methods of their use
SG11201809537VA (en) Urea motif containing compounds and derivatives thereof as antibacterial drugs
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors